Common name: Fisetin
CAS NO.: 528-48-3
Molecular Formula: C15-H10-O6
Molecular Weight: 286.24
Structure:

Specification: 10%, 50% , 98%
Test method: HPLC
Packing: 25KG/ cardboard drum
Storage: Store in cool and dry place and keep away from strong direct light and heat
Shelf Life: Two years when properly stored
Please see the typical HPLC of 98% Fisetin as follow:

Applications:

What is Fisetin?

Fisetin is a flavonol (3,7,3',4'-tetrahydroxyflavone) that has anti-inflammatory and antiproliferative effects. According to recent research, Fisetin, may protect the brain against Alzheimer’s, dementia, and age-related memory loss.

Health Benefits of Fisetin

Brain health

In vitro studies show fisetin has a strong anti-inflammatory activity in brain microglia, and could be a potential therapeutic agent for the treatment of neuroinflammatory diseases.

Huntington's disease

Fisetin slows the onset of motor problems and delays death in three models of Huntington's disease, according to researchers at the Salk Institute for Biological Studies. Human Molecular Genetics, 2010.

Fisetin and memory

Mice studies indicate that fisetin may be helpful for memory. Pamela Maher, Ph.D., a senior staff scientist in the Salk Cellular Neurobiology Laboratory, has found that it exerts its neuroprotective and memory-enhancing effects through the activation of the Ras/ERK signaling pathway.

Prostate cancer

Fisetin, a novel dietary flavonoid causes apoptosis and cell-cycle arrest in human prostate cancer LNCaP cells. Carcinogenesis. 2008. The aim of this study was to determine the effect of fisetin, a tetrahydroxyflavone, on inhibition of cell-growth and induction of apoptosis in human prostate cancer cells.
Treatment of fisetin was found to result in a decrease in the viability of LNCaP, CWR22Rupsilon1 and PC-3 cells but had only minimal effects on normal prostate epithelial PrEC cells. Treatment of LNCaP cells with fisetin also resulted in G1-phase arrest which was associated with a marked decrease in the protein expression of cyclin D1, D2 and E and their activating partner cdk2, 4 and 6 with concomitant induction of WAF1/p21 and KIP1/p27.